The completion of the $3.0 million common share repurchase program demonstrates Pyxis Tankers' commitment to returning value to shareholders and potentially enhancing share price. Redemption of ...
Maroussi, Greece – January 30, 2025 – Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS), (“we”, “our”, “us”, the “Company” or “Pyxis Tankers”), an ...
Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback